Geographic Atrophy Overview
Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the disease landscape of geographic atrophy.
Evolution of Access to Treatment for Wet AMD/DME Therapies
Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.
Wet AMD Resource Utilization Impacted by Medication Duration of Action
Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.
Medication Burden and Stigma Impacting Adherence Rates in Patients With MDR HIV
Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment.
Payers and Clinicians Impacted by CD4 Recovery
Dr Sension underlines the value of CD4 recovery from payer and clinician perspectives.
Examining the Role of ctDNA
The effect of ctDNA in the GI cancer treatment landscape are illustrated by Dr Marshall.
Utilization Management Strategies in Treatment of Wet AMD and DME
Veeral Sheth, MD, MBA, FACS, Joseph Coney, MD, FASRS, FACS, and Caesar Luo, MD, FASRS, FACS discuss their experience with utilization management strategies.
Treatment Barriers Facing Patients With DME and Wet AMD
Caesar Luo, MD, FASRS, FACS discusses the biggest barriers for patients with wet AMD and DME to receiving optimal treatment and his strategies to overcome these barriers.
Considerations with Non-Adherence to Standard Background MDR HIV Therapy
Key opinion leaders highlight barriers to MDR HIV treatment adherence.
Patient and Payer Considerations for Medication Regimen Adherence In MDR HIV Treatment Pathway
The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.
ASCO GI 2023: SUNLIGHT Study
John L. Marshall, MD, provides insight into the SUNLIGHT study findings presented during the 2023 ASCO Gastrointestinal Cancers Symposium.
HoFH Treatments on the Horizon
In their final thoughts, Drs Brinton, Baum and Michos provide insights on the trajectory of treatment in HoFH.
Unmet Needs in Treatment of HoFH
Medical experts discuss the unmet needs surrounding homozygous FH.
Diagnostic Imaging Impacting DME and Wet AMD Treatment Landscape
A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.
Novel Treatment Mechanisms for Patients with DME and Wet AMD
Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.
MDR HIV Treatment Approaches and Considerations for Therapeutic Adjustments
Therapy adjustments in MDR HIV are explored by Dr Sension.
Pharmacotherapeutic Treatment Options for Treating MDR HIV
Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.
How Payers can Improve Access to Care for Patients
Drs Michos and Baum provide payer considerations regarding HoFH treatment pathways.
Navigating Required Documentation for Treatment in HoFH
Considerations for authorization documentation in HoFH treatment are discussed.
Social Determinants of Health Impacting Patients Diagnosed with MDR HIV
Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.
Clinical Considerations for Retreatment in Failed Anti-VEGF Therapy
Veeral Sheth, MD, MBA, FACS discusses re-treatment in patients with wet AMD who have previously failed an anti-VEGF therapy.
Economic and Social Burdens Associated with MDR HIV
A panel of experts explore burdens impacting patients diagnosed with MDR HIV.
Faricimab Approved Label Dosing Interval
Dr Coney expands on the role and impact of approved label dosing of faricimab.
Final Thoughts on BTK Inhibitors
The panel of experts provide their closing thoughts on the burden of disease in leukemia and lymphoma and the Bruton tyrosine kinase inhibitor landscape.
The Future of BTK Inhibitors
Callie Coombs, MD, and Roy Beveridge, MD, discuss the education needed for payers and physicians surrounding the use of the Bruton tyrosine kinase inhibitors.
Final Thoughts on Psoriasis Across Skin Types
A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.
Health Equity Across All Skin Phototypes
Incentivizing Patient Use of Digital Health Tools
Maria Lopes, MD, MS, and Amy McMichael, MD, discuss how payers can incentivize patients’ use of digital health tools to monitor the success or failure of treatment.
Barriers to Care Access for Patients with HoFH
Drs Baum and Michos share insights on current barriers to access of care.
Lomitapide and Evinacumab for Treatment of HoFH: Part 2
Evinacumab is highlighted as a new therapy for treating patients with homozygous FH.
